0001213900-26-051125
SEC filingApimeds Pharmaceuticals US, Inc. entered into a Confidential Settlement Agreement resolving merger disputes, with Lokahi retaining Apitox program assets and contributing $4M working capital, alongside a Forbearance Agreement on $11M convertible note.
The Settlement Agreement marks a comprehensive resolution to ongoing disputes stemming from the December 1, 2025 Merger Agreement involving MindWave and Lokahi acquisitions, averting further litigation including the dismissal of the Lokahi Action in New York federal court. Lokahi's retention of the Apitox program, encompassing key intellectual property, regulatory materials, and a $2.2M CRO credit, alongside the $4M cash infusion and forgiveness of a $750K advance, provides immediate liquidity to the Company while reallocating 51% of Lokahi's common stock to Erik Emerson. The formation of Newco, funded by 10% of investor financing proceeds and slated for spin-off within 12-24 months, introduces a new independent operational entity. Concurrently, the Forbearance Agreement with Alto Opportunity Master Fund halts enforcement actions on multiple defaults under the $11M senior convertible note, including filing delays and stockholder approval failures, contingent on strict milestones like 10-K filing by April 30, 2026, registration effectiveness, and NYSE relisting by June 30, 2026. Board stabilization reaffirms the current directors' positions, voiding prior consents, with planned transition to independent directors post-10-K to support NYSE compliance. The irrevocable proxy ensures Inscobee cooperation on critical proposals like preferred stock conversion, note approvals, and 1-for-10 reverse split, critical for lifting the NYSE trading halt and resuming operations. These agreements de-risk near-term default risks and corporate governance instability, enabling focus on financing execution and regulatory remediation.